Skip to main content
PMC home page
British Heart Journal logoLink to British Heart Journal
. 1994 Jun;71(6):504–507. doi: 10.1136/hrt.71.6.504

Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease.

D de Bono 1
PMCID: PMC1025439  PMID: 8043326

Full text

PDF
504

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alessi M. C., Juhan-Vague I., Kooistra T., Declerck P. J., Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemost. 1988 Dec 22;60(3):491–494. [PubMed] [Google Scholar]
  2. Andreotti F., Davies G. J., Hackett D. R., Khan M. I., De Bart A. C., Aber V. R., Maseri A., Kluft C. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. Am J Cardiol. 1988 Sep 15;62(9):635–637. doi: 10.1016/0002-9149(88)90669-8. [DOI] [PubMed] [Google Scholar]
  3. Auwerx J., Bouillon R., Collen D., Geboers J. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis. 1988 Jan-Feb;8(1):68–72. doi: 10.1161/01.atv.8.1.68. [DOI] [PubMed] [Google Scholar]
  4. Clowes A. W., Clowes M. M., Au Y. P., Reidy M. A., Belin D. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res. 1990 Jul;67(1):61–67. doi: 10.1161/01.res.67.1.61. [DOI] [PubMed] [Google Scholar]
  5. Clowes A. W., Clowes M. M., Kirkman T. R., Jackson C. L., Au Y. P., Kenagy R. Heparin inhibits the expression of tissue-type plasminogen activator by smooth muscle cells in injured rat carotid artery. Circ Res. 1992 Jun;70(6):1128–1136. doi: 10.1161/01.res.70.6.1128. [DOI] [PubMed] [Google Scholar]
  6. Cooke J. P., Stamler J., Andon N., Davies P. F., McKinley G., Loscalzo J. Flow stimulates endothelial cells to release a nitrovasodilator that is potentiated by reduced thiol. Am J Physiol. 1990 Sep;259(3 Pt 2):H804–H812. doi: 10.1152/ajpheart.1990.259.3.H804. [DOI] [PubMed] [Google Scholar]
  7. Dawson S., Hamsten A., Wiman B., Henney A., Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb. 1991 Jan-Feb;11(1):183–190. doi: 10.1161/01.atv.11.1.183. [DOI] [PubMed] [Google Scholar]
  8. Diamond S. L., Eskin S. G., McIntire L. V. Fluid flow stimulates tissue plasminogen activator secretion by cultured human endothelial cells. Science. 1989 Mar 17;243(4897):1483–1485. doi: 10.1126/science.2467379. [DOI] [PubMed] [Google Scholar]
  9. Diéval J., Nguyen G., Gross S., Delobel J., Kruithof E. K. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1. Blood. 1991 Feb 1;77(3):528–532. [PubMed] [Google Scholar]
  10. Erickson L. A., Fici G. J., Lund J. E., Boyle T. P., Polites H. G., Marotti K. R. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature. 1990 Jul 5;346(6279):74–76. doi: 10.1038/346074a0. [DOI] [PubMed] [Google Scholar]
  11. FEARNLEY G. R., BALMFORTH G., FEARNLEY E. Evidence of a diurnal fibrinolytic rhythm; with a simple method of measuring natural fibrinolysis. Clin Sci. 1957 Nov;16(4):645–650. [PubMed] [Google Scholar]
  12. Fay W. P., Shapiro A. D., Shih J. L., Schleef R. R., Ginsburg D. Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med. 1992 Dec 10;327(24):1729–1733. doi: 10.1056/NEJM199212103272406. [DOI] [PubMed] [Google Scholar]
  13. Galiñanes M., Mullane K. M., Bullough D., Hearse D. J. Acadesine and myocardial protection. Studies of time of administration and dose-response relations in the rat. Circulation. 1992 Aug;86(2):598–608. doi: 10.1161/01.cir.86.2.598. [DOI] [PubMed] [Google Scholar]
  14. Gray R. P., Yudkin J. S., Patterson D. L. Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic patients. Br Heart J. 1993 Mar;69(3):228–232. doi: 10.1136/hrt.69.3.228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hamsten A., Wiman B., de Faire U., Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985 Dec 19;313(25):1557–1563. doi: 10.1056/NEJM198512193132501. [DOI] [PubMed] [Google Scholar]
  16. Hamsten A., de Faire U., Walldius G., Dahlén G., Szamosi A., Landou C., Blombäck M., Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987 Jul 4;2(8549):3–9. doi: 10.1016/s0140-6736(87)93050-9. [DOI] [PubMed] [Google Scholar]
  17. Hekman C. M., Loskutoff D. J. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem. 1985 Sep 25;260(21):11581–11587. [PubMed] [Google Scholar]
  18. Jansson J. H., Nilsson T. K., Olofsson B. O. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J. 1991 Feb;12(2):157–161. doi: 10.1093/oxfordjournals.eurheartj.a059862. [DOI] [PubMed] [Google Scholar]
  19. Juhan-Vague I., Alessi M. C., Fossat C., Declerck P. J., Kruithof E. K. Plasma determination of plasminogen activator inhibitor 1 antigen must be performed in blood collected on antiplatelet/anticoagulant mixture. Thromb Haemost. 1987 Dec 18;58(4):1096–1096. [PubMed] [Google Scholar]
  20. Juhan-Vague I., Alessi M. C., Raccah D., Aillaud M. F., Billerey M., Ansaldi J., Philip-Joet C., Vague P. Daytime fluctuations of plasminogen activator inhibitor 1 (PAI-1) in populations with high PAI-1 levels. Thromb Haemost. 1992 Jan 23;67(1):76–82. [PubMed] [Google Scholar]
  21. Juhan-Vague I., Roul C., Alessi M. C., Ardissone J. P., Heim M., Vague P. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients--relationship with plasma insulin. Thromb Haemost. 1989 Jun 30;61(3):370–373. [PubMed] [Google Scholar]
  22. Kluft C., Jie A. F., Rijken D. C., Verheijen J. H. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1). Thromb Haemost. 1988 Apr 8;59(2):329–332. [PubMed] [Google Scholar]
  23. Kooistra T., Bosma P. J., Töns H. A., van den Berg A. P., Meyer P., Princen H. M. Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemost. 1989 Sep 29;62(2):723–728. [PubMed] [Google Scholar]
  24. Landin K., Tengborn L., Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med. 1990 Apr;227(4):273–278. doi: 10.1111/j.1365-2796.1990.tb00157.x. [DOI] [PubMed] [Google Scholar]
  25. Loskutoff D. J., Edgington T. E. Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. Proc Natl Acad Sci U S A. 1977 Sep;74(9):3903–3907. doi: 10.1073/pnas.74.9.3903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Loskutoff D. J., Sawdey M., Keeton M., Schneiderman J. Regulation of PAI-1 gene expression in vivo. Thromb Haemost. 1993 Jul 1;70(1):135–137. [PubMed] [Google Scholar]
  27. Meade T. W., Ruddock V., Stirling Y., Chakrabarti R., Miller G. J. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 1993 Oct 30;342(8879):1076–1079. doi: 10.1016/0140-6736(93)92062-x. [DOI] [PubMed] [Google Scholar]
  28. Mehta J., Mehta P., Lawson D., Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. J Am Coll Cardiol. 1987 Feb;9(2):263–268. doi: 10.1016/s0735-1097(87)80373-x. [DOI] [PubMed] [Google Scholar]
  29. Nilsson I. M., Felding P., Lecander I., Lennér C., Astedt B. Different types of plasminogen activator inhibitors in plasma and platelets in pregnant women. Br J Haematol. 1986 Feb;62(2):215–220. doi: 10.1111/j.1365-2141.1986.tb02924.x. [DOI] [PubMed] [Google Scholar]
  30. Nollert M. U., Eskin S. G., McIntire L. V. Shear stress increases inositol trisphosphate levels in human endothelial cells. Biochem Biophys Res Commun. 1990 Jul 16;170(1):281–287. doi: 10.1016/0006-291x(90)91271-s. [DOI] [PubMed] [Google Scholar]
  31. Olofsson B. O., Dahlén G., Nilsson T. K. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J. 1989 Jan;10(1):77–82. doi: 10.1093/oxfordjournals.eurheartj.a059384. [DOI] [PubMed] [Google Scholar]
  32. Oseroff A., Krishnamurti C., Hassett A., Tang D., Alving B. Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease. J Lab Clin Med. 1989 Jan;113(1):88–93. [PubMed] [Google Scholar]
  33. Ridker P. M., Vaughan D. E., Stampfer M. J., Manson J. E., Hennekens C. H. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 1993 May 8;341(8854):1165–1168. doi: 10.1016/0140-6736(93)90998-v. [DOI] [PubMed] [Google Scholar]
  34. Schleef R. R., Bevilacqua M. P., Sawdey M., Gimbrone M. A., Jr, Loskutoff D. J. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem. 1988 Apr 25;263(12):5797–5803. [PubMed] [Google Scholar]
  35. Schleef R. R., Higgins D. L., Pillemer E., Levitt L. J. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest. 1989 May;83(5):1747–1752. doi: 10.1172/JCI114076. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Stiko-Rahm A., Wiman B., Hamsten A., Nilsson J. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis. 1990 Nov-Dec;10(6):1067–1073. doi: 10.1161/01.atv.10.6.1067. [DOI] [PubMed] [Google Scholar]
  37. Underwood M. J., De Bono D. P. Increased fibrinolytic activity in the intima of atheromatous coronary arteries: protection at a price. Cardiovasc Res. 1993 May;27(5):882–885. doi: 10.1093/cvr/27.5.882. [DOI] [PubMed] [Google Scholar]
  38. Zoellner H., Wojta J., Gallicchio M., McGrath K., Hamilton J. A. Cytokine regulation of the synthesis of plasminogen activator inhibitor-2 by human vascular endothelial cells. Comparison with plasminogen activator inhibitor-1 synthesis. Thromb Haemost. 1993 Feb 1;69(2):135–140. [PubMed] [Google Scholar]
  39. de Boer A., Kluft C., Kroon J. M., Kasper F. J., Schoemaker H. C., Pruis J., Breimer D. D., Soons P. A., Emeis J. J., Cohen A. F. Liver blood flow as a major determinant of the clearance of recombinant human tissue-type plasminogen activator. Thromb Haemost. 1992 Jan 23;67(1):83–87. [PubMed] [Google Scholar]
  40. van Hinsbergh V. W. Regulation of the synthesis and secretion of plasminogen activators by endothelial cells. Haemostasis. 1988;18(4-6):307–327. doi: 10.1159/000215814. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES